Drug-Induced Immune Haemolytic Anaemia: A Decade Review by Abdul Mannan
Abdul Mannan, Consultant Haematologist at Betsi Cadwaladr University Health Board, shared on LinkedIn:
”Sometimes diagnosing drug-induced immune haemolytic anaemia (DIIHA) feels like chasing a unicorn among zebras.
What looks like a straightforward AIHA can suddenly turn on its head when a culprit drug is revealed.
A decade of pharmacovigilance data from France has now reminded us that the “usual suspects” (antibiotics, anti-inflammatories, etc.) are no longer alone—immune checkpoint inhibitors have officially joined the list.
The lesson is clear:
- Never underestimate the power of a careful drug history.
- A positive DAT is not the end of the story—it’s the start of the detective work.
- Always challenge your diagnostic assumptions before risking re-exposure.
As our therapeutic toolbox expands, so too does the responsibility to spot these rare but serious events.
Grateful for the international haematology community that keeps pushing vigilance forward and protecting patients.”
Read the full paper in BJ Haem.
Article: A decade of pharmacovigilance in France: Immune checkpoints join the list of usual suspects for drug-induced immune haemolytic anaemia
Authors: Guillaume Brenac, Anne Dautriche, Romane Freppel, Anthony Facile, Bruno Revol, Mathilde Beurrier, Bernard Bonnotte, Sylvain Audia
Stay informed on all the scientific advances in Hematology with Hemostasis Today.
-
Oct 28, 2025, 14:27Maha Othman on 10-Year Anniversary of the CanVECTOR Research Network!
-
Oct 28, 2025, 14:00Claudio Laudani on PCSK9 Association with Increased Platelet Reactivity: A Pooled Analysis
-
Oct 28, 2025, 13:31Laurent Bertoletti Invites You to The INNOVTE and GITA Joined Meeting on Hormones and Thrombosis
-
Oct 28, 2025, 12:28Courtney Lawrence: Honored to Team Up with BET on Blood at AABB 2025
-
Oct 27, 2025, 19:45Benedikt Lorenz on Liver Failure and Coagulation – Myths, Traps, and Bad Habits
-
Oct 28, 2025, 13:09Gregory Piazza on CORONA-VTE Network Analysis
-
Oct 27, 2025, 18:42Khaled Musallam Shares BEYOND Trial Phase 2 Insights on Luspatercept Use in NTD β-Thalassaemia
-
Oct 27, 2025, 13:30Fabrice Cognasse: When Platelets Meet Artificial Intelligence!
-
Oct 27, 2025, 13:00Hossam El Benawi Shares Multi Site LVT Study from Mayo Clinic
-
Oct 27, 2025, 08:01Acquired Hemophilia A (AHA) is Rare and Often Missed - RPTH Journal
-
Oct 25, 2025, 07:42Adithya Hande: India’s Silent Killer and a Scientific Breakthrough
-
Oct 23, 2025, 09:57Arun V. J: Artificial Blood Is Closer Than You Think
-
Oct 23, 2025, 07:11Sebastien Lobet Presented the ACTIVLIM-Hemo Scale
-
Oct 23, 2025, 07:05Syed Ehsan Shah on Advantages of Werfen HemoCell Automation
-
Oct 22, 2025, 08:25Johanna Nystedt: Not Every Day We Can Release a New Blood Product to Meet An Unmet Medical Need!
-
Oct 27, 2025, 15:10David McIntosh: Making Measurable Progress – Towards a World in Which No-one Ever Dies from Lack of a Vital Plasma-Derived Medicine
-
Oct 27, 2025, 13:18Stroke Foundation Welcomes Jacqui McCallum as the New Executive Director
-
Oct 27, 2025, 12:54Guillermo Lahera Forteza on Stroke and Mental Health
-
Oct 27, 2025, 12:37Joshua Ngimbwa Recognised as the Best Male Junior Investigator Awardee at the Tanzania Health Summit
-
Oct 27, 2025, 08:00Rohit Gosain: Revumenib is Now FDA Approved for R/R AML with NPM1 Mutation